BCRX  Biocryst Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

209.29M

Vuru Grade

23.50/100

Current Price

$2.84
-0.10 (-3.40%)

Company Metrics

  • P/E 0
  • P/S 4.68
  • P/B 7.80
  • EPS -0.69
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / N/A %
  • Avg. Vol. 929,642.00
  • Shares 73.69M
  • Market Cap. 209.29M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
Motley Fool - Oct 8, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results - TheStreet.com
BioCryst Announces Successful Phase 1 Clinical Trial of BCX7353 - GlobeNewswire (press release)
Biocryst Pharmaceuticals Incorporated (NASDAQ:BCRX) Shorted Shares Decreased ...
Engelwood Daily - 13 hours ago
The short interest to Biocryst Pharmaceuticals Incorporated's float is 11.45%. The stock decreased 3.40% or $0.1 on June 24, hitting $2.84.
HC Wainwright Maintains Buy On BioCryst Pharmaceuticals, Inc. (BCRX) Following ...
Smarter Analyst - May 6, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares slipped yesterday 9% after the drug discovery company reported first-quarter results and update on its clinical progress.
New Roundup- Medivation (NASDAQ:MDVN), St. Jude Medical (NYSE:STJ), BioCryst ... - Seneca Globe
Biocryst Pharmaceuticals (BCRX) Is Today's Strong On High Volume Stock
TheStreet.com - Jun 7, 2016
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Updated Analyst Coverage - Risers & Fallers
Which way BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) earnings may go - iStreetWire
Analyst Review Alert: BioCryst Pharmaceuticals Inc (BCRX)
CWRU Observer - Jun 10, 2016
Analysts are weighing in on how BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.6.
Stock Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Announces Clinical ...
Smarter Analyst - Feb 8, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary ...
Is BioCryst Reaching Crush Depth? - 24/7 Wall St.
BioCryst Pharmaceuticals, Inc Crashes on Failure of OPuS 2 Clinical Trial for HAE - Bidness ETC
Schwab Charles Investment Management Inc. Acquires 20210 Shares of BioCryst ...
The Vista Voice - Apr 25, 2016
BioCryst Pharmaceuticals logo Schwab Charles Investment Management Inc. raised its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 8.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange ...
Stock's Buzz on These Trending Stocks BioCryst Pharmaceuticals, Inc. (NASDAQ ... - The Point Review
BioCryst Pharmaceuticals, Inc. (BCRX) has potential to increase 313 percent
CWRU Observer - Apr 26, 2016
BioCryst Pharmaceuticals, Inc. (BCRX) has just caught the analyst's attention after adding 5.22 percent in the last trading session.
Analysts: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Could Go to 15.00
CWRU Observer - Jun 10, 2016
Analysts are weighing in on how BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) , might perform in the near term. Wall Street analysts have a much less favorable assessment of the stock, with a mean rating of 2.6.
Overview of Price Moves: Zoetis Inc. (NYSE:ZTS) , BioCryst Pharmaceuticals ... - Street Updates
Upgrades And Downgrades For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Risers & Fallers
Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $8.78
South Florida Hedge Fund Managers - Apr 2, 2016
BioCryst Pharmaceuticals logo Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have earned a consensus rating of “Hold” from the fourteen research firms that are currently covering the firm, MarketBeat.